We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
5
2 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Active, not recruiting
2
40.0%
Completed
Recruiting
1
20.0%
No approval data available
- The pneumococcal disease pipeline features over 20 drugs from 18+ companies in various clinical and preclinical stages, addressing a significant global health threat. - Sanofi's PCV21, a 21-valent pneumococcal conjugate vaccine in Phase III, leads the late-stage pipeline targeting both pediatric and adult populations worldwide. - Vaxcyte's VAX-31 received FDA Breakthrough Therapy designation and showed strong immune responses in Phase I/II trials involving 1,015 adults aged 50 and older. - The market is driven by high global disease burden, rising antimicrobial resistance, and expanded immunization initiatives, particularly in developing regions.
